• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Presidio Pharmaceuticals

edit

Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the discovery, in-licensing, development and commercialization of novel therapeutics for viral infections, including HCV and HIV. Presidio has raised over $27 million in financing from Panorama Capital, Baker Brothers Investments, Bay City Capital, Ventures West, Nexus Medical Partners, and Sagamore Bioventures LLC.

Milestones

edit

• 
  Presidio Pharmaceuticals added Mehdi Maghsoodnia as COO.
  Posted 1/15/09 at 3:50pm
• 
  Presidio Pharmaceuticals received $26M in Series B funding. (8/29/07)
  Posted 7/24/09 at 12:51am via presidiopharma.com
• 
  Presidio Pharmaceuticals received $27M in Unattributed funding. (7/10/09)
  Posted 7/13/09 at 3:28pm via fiercebiotech.com

Videos

Screenshots

edit

Above: Presidio
Uploaded: 7/24/09

Sources

1. Presidio Pharmaceuticals Closes $26 Million Series B Financing (presidiopharma.com) [edit]
2. Presidio rounds up $27M for clinical studies (fiercebiotech.com) [edit]